Chondrosarcoma classification: Difference between revisions
(Mahshid) |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chondrosarcoma}} | {{Chondrosarcoma}} | ||
{{CMG}};{{AE}} {{ | |||
{{CMG}}; {{AE}} {{Rohan}} | |||
==Overview== | ==Overview== | ||
There is no established system for the classification of [disease name]. | |||
OR | |||
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4]. | |||
OR | |||
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. | |||
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3]. | |||
OR | |||
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic. | |||
OR | |||
If the staging system involves specific and characteristic findings and features: | |||
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2]. | |||
OR | |||
The staging of [malignancy name] is based on the [staging system]. | |||
OR | |||
There is no established system for the staging of [malignancy name]. | |||
==Classification== | ==Classification== | ||
Chondrosarcoma may be classified into | *Chondrosarcoma be classified based on histological findings, location and imaging findings. | ||
===Histological Classification=== | |||
*Chondrosarcoma may be classified based on histological findings into following groups:<ref name="pmid8378694">{{cite journal| author=Raymond E, L'Her P, Jeanbourquin D, Schill H, Jancovici R, Daly JP et al.| title=[Chondrosarcoma of the thoracic wall. Review of the literature apropos of 4 cases]. | journal=Rev Pneumol Clin | year= 1993 | volume= 49 | issue= 1 | pages= 19-25 | pmid=8378694 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8378694 }} </ref><ref name="pmid30559960">{{cite journal| author=Lex JR, Evans S, Stevenson JD, Parry M, Jeys LM, Grimer RJ| title=Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment. | journal=Clin Sarcoma Res | year= 2018 | volume= 8 | issue= | pages= 23 | pmid=30559960 | doi=10.1186/s13569-018-0110-1 | pmc=6293503 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30559960 }} </ref> | |||
'''Primary Chondrosarcoma''' | |||
*Chondrosarcoma that arises denovo and comprises of following subtypes: | |||
**Conventional chondrosarcoma - Low-grade, high-grade, and dedifferentiated chondrosarcoma (90% of all chondrosarcomas) | |||
**Clear cell chondrosarcoma (1% of all chondrosarcomas) | |||
**Mesenchymal chondrosarcoma (2% of all chondrosarcomas) | |||
'''Secondary Chondrosarcoma''' | |||
*Chondrosarcoma that arises from benign cartilage lesions includes (7% of all chondrosarcomas): | |||
**Osteochondroma (<1% risk of malignant transfomation) | |||
**Multiple hereditary exostosis (1-10% risk of malignant transformation) | |||
**Enchondromas (1% risk of malignant transformation) | |||
**Ollier's disease (25-40% risk of malignant transformation) | |||
**Maffucci's disease(100% risk of malignant transformation) | |||
===Based on Location=== | |||
*Chondrosarcoma may be classified based on location into following groups:<ref name="pmid19411454">{{cite journal| author=Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP| title=Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. | journal=J Bone Joint Surg Am | year= 2009 | volume= 91 | issue= 5 | pages= 1063-72 | pmid=19411454 | doi=10.2106/JBJS.H.00416 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19411454 }} </ref><ref name="pmid17908885">{{cite journal| author=Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group| title=Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. | journal=J Bone Joint Surg Am | year= 2007 | volume= 89 | issue= 10 | pages= 2113-23 | pmid=17908885 | doi=10.2106/JBJS.F.01530 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17908885 }} </ref> | |||
**Centrally located within the medullary cavity. (central chondrosarcoma) (70% of all chondrosarcomas) | |||
**Peripherally located on the surface of bone as a result of malignant transformation within the cartilaginous cap. (Peripheral chondrosarcoma) (15% of all chondrosarcomas) | |||
===Enneking (MSTS) Staging System=== | |||
*The Enneking surgical staging system (also known as the MSTS system) for malignant [[Musculoskeletal system|musculoskeletal]] [[Tumor|tumors]] based on [[radiographic]] characteristics of the tumor host margin.<ref name="pmid20333492">{{cite journal| author=Jawad MU, Scully SP| title=In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system. | journal=Clin Orthop Relat Res | year= 2010 | volume= 468 | issue= 7 | pages= 2000-2 | pmid=20333492 | doi=10.1007/s11999-010-1315-7 | pmc=2882012 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20333492 }} </ref> | |||
*It is widely accepted and routinely used classification. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | |||
| valign="top" | | |||
|- | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Stages}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |1 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Latent: Well demarcated borders | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |2 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Active: Indistinct borders | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |3 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Aggressive: Indistinct borders | |||
|} | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Orthopedics]] | [[Category:Orthopedics]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Skeletal disorders]] | [[Category:Skeletal disorders]] | ||
Revision as of 16:24, 22 January 2019
Chondrosarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Chondrosarcoma classification On the Web |
American Roentgen Ray Society Images of Chondrosarcoma classification |
Risk calculators and risk factors for Chondrosarcoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
- Chondrosarcoma be classified based on histological findings, location and imaging findings.
Histological Classification
Primary Chondrosarcoma
- Chondrosarcoma that arises denovo and comprises of following subtypes:
- Conventional chondrosarcoma - Low-grade, high-grade, and dedifferentiated chondrosarcoma (90% of all chondrosarcomas)
- Clear cell chondrosarcoma (1% of all chondrosarcomas)
- Mesenchymal chondrosarcoma (2% of all chondrosarcomas)
Secondary Chondrosarcoma
- Chondrosarcoma that arises from benign cartilage lesions includes (7% of all chondrosarcomas):
- Osteochondroma (<1% risk of malignant transfomation)
- Multiple hereditary exostosis (1-10% risk of malignant transformation)
- Enchondromas (1% risk of malignant transformation)
- Ollier's disease (25-40% risk of malignant transformation)
- Maffucci's disease(100% risk of malignant transformation)
Based on Location
- Chondrosarcoma may be classified based on location into following groups:[3][4]
- Centrally located within the medullary cavity. (central chondrosarcoma) (70% of all chondrosarcomas)
- Peripherally located on the surface of bone as a result of malignant transformation within the cartilaginous cap. (Peripheral chondrosarcoma) (15% of all chondrosarcomas)
Enneking (MSTS) Staging System
- The Enneking surgical staging system (also known as the MSTS system) for malignant musculoskeletal tumors based on radiographic characteristics of the tumor host margin.[5]
- It is widely accepted and routinely used classification.
Stages | Description |
---|---|
1 | Latent: Well demarcated borders |
2 | Active: Indistinct borders |
3 | Aggressive: Indistinct borders |
References
- ↑ Raymond E, L'Her P, Jeanbourquin D, Schill H, Jancovici R, Daly JP; et al. (1993). "[Chondrosarcoma of the thoracic wall. Review of the literature apropos of 4 cases]". Rev Pneumol Clin. 49 (1): 19–25. PMID 8378694.
- ↑ Lex JR, Evans S, Stevenson JD, Parry M, Jeys LM, Grimer RJ (2018). "Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment". Clin Sarcoma Res. 8: 23. doi:10.1186/s13569-018-0110-1. PMC 6293503. PMID 30559960.
- ↑ Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP (2009). "Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database". J Bone Joint Surg Am. 91 (5): 1063–72. doi:10.2106/JBJS.H.00416. PMID 19411454.
- ↑ Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group (2007). "Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones". J Bone Joint Surg Am. 89 (10): 2113–23. doi:10.2106/JBJS.F.01530. PMID 17908885.
- ↑ Jawad MU, Scully SP (2010). "In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system". Clin Orthop Relat Res. 468 (7): 2000–2. doi:10.1007/s11999-010-1315-7. PMC 2882012. PMID 20333492.